Last kr0.84 SEK
Change Today -0.015 / -1.76%
Volume 218.2K
KARO On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 4:35 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

karo bio ab (KARO) Snapshot

Open
kr0.84
Previous Close
kr0.85
Day High
kr0.85
Day Low
kr0.83
52 Week High
03/19/14 - kr1.13
52 Week Low
08/22/13 - kr0.25
Market Cap
564.7M
Average Volume 10 Days
1.7M
EPS TTM
kr-0.05
Shares Outstanding
676.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KARO BIO AB (KARO)

Related News

No related news articles were found.

karo bio ab (KARO) Related Businessweek News

No Related Businessweek News Found

karo bio ab (KARO) Details

Karo Bio AB (publ), a pharmaceutical company, focuses on the research and development of drugs for unmet medical needs primarily in Sweden. The company is involved in the preclinical development of drugs primarily in the fields of neuropsychiatry, inflammation, autoimmune diseases, and cancer. Its pipeline products include nuclear receptor that regulates various functions in the body affecting a range of diseases, such as inflammation, diabetes, dyslipidemia and osteoporosis, obesity, and certain forms of cancer; estrogen receptor beta for use in the areas of women’s health, depression, and certain forms of cancer; and RORgamma for the treatment of autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, psoriasis, and multiple sclerosis. The company has collaboration agreements with Pfizer Inc. to discover and develop compounds for the treatment of autoimmune diseases; and 4D Science GmbH to develop treatments for fibrotic diseases. Karo Bio AB (publ) was founded in 1987 and is headquartered in Huddinge, Sweden.

40 Employees
Last Reported Date: 07/11/14
Founded in 1987

karo bio ab (KARO) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr2.0M
Compensation as of Fiscal Year 2013.

karo bio ab (KARO) Key Developments

Karo Bio Announces Consolidated and Parent Earnings Results for the Second Quarter and First Half Year Ended June 30, 2014

Karo Bio announced consolidated and parent earnings results for the second quarter and first half year ended June 30, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 6,825,000 against SEK 8,110,000 a year ago. Operating loss was SEK 14,291,000 against SEK 14,682,000 a year ago. Loss after financial items was SEK 14,215,000 against SEK 14,582,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 14,215,000 against SEK 14,582,000 a year ago. Loss per share was SEK 0.02 against SEK 0.03 a year ago. Cash flow used in operating activities was SEK 13,145,000 against SEK 14,256,000 a year ago. For the half year, on consolidated basis, the company reported net sales of SEK 13,185,000 against SEK 16,209,000 a year ago. Operating loss was SEK 27,689,000 against SEK 25,364,000 a year ago. Loss after financial items was SEK 27,593,000 against SEK 25,251,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 27,593,000 against SEK 25,251,000 a year ago. Loss per share was SEK 0.04 against SEK 0.04 a year ago. Cash flow used in operating activities was SEK 26,282,000 against SEK 24,176,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 6,825,000 against SEK 8,110,000 a year ago. Operating loss was SEK 14,306,000 against SEK 14,700,000 a year ago. Loss after financial items was SEK 14,228,000 against SEK 14,596,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 14,228,000 against SEK 14,596,000 a year ago. For the half year, on consolidated basis, the company reported net sales of SEK 13,185,000 against SEK 16,209,000 a year ago. Operating loss was SEK 27,704,000 against SEK 25,383,000 a year ago. Loss after financial items was SEK 27,603,000 against SEK 25,262,000 a year ago. Net loss for the period attributable to shareholders of the parent company was SEK 27,603,000 against SEK 25,262,000 a year ago.

Karo Bio Aktiebolag (publ) Announces Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2014

Karo Bio Aktiebolag (publ) announced consolidated and parent earnings results for the first quarter ended March 31, 2014. For the quarter, on consolidated basis, the company's net sales were SEK 6.4 million compared with SEK 8.1 million a year ago. Operating loss was SEK 13.4 million compared with SEK 10.7 million a year ago. Net loss for the period was SEK 13.4 million compared with SEK 10.7 million a year ago. Net earnings for the period attributable to shareholders of the parent company were SEK 13.4 million or SEK 0.03 per share compared with SEK 10.7 million or SEK 0.02 per share a year ago. Cash flow used in operating activities was SEK 13.1 million compared with SEK 9.9 million a year ago. Net investment in equipment was SEK 1.1 million compared with SEK 0.42 million a year ago. For the quarter, on parent basis, the company's net sales were SEK 6.4 million compared with SEK 8.1 million a year ago. Operating loss was SEK 13.4 million compared with SEK 10.7 million a year ago. Net loss for the period was SEK 13.4 million compared with SEK 10.7 million a year ago.

Karo Bio Aktiebolag (publ), Q1 2014 Earnings Call, May 08, 2014

Karo Bio Aktiebolag (publ), Q1 2014 Earnings Call, May 08, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KARO:SS kr0.84 SEK -0.015

KARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KARO.
View Industry Companies
 

Industry Analysis

KARO

Industry Average

Valuation KARO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KARO BIO AB, please visit www.karobio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.